RxDoctor Payments Data

Haval Saadlla, MD

Pulmonary Disease · Chillicothe, OHNPI 1659458156

Payments from drug & device makers

$48,999in general payments, 2019–2025

Across 265 payments — averaging $184.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$41K
  • Intuitive Surgical$4K
  • Pulmonx Corporation$988
  • Boehringer Ingelheim$471
  • GSK$437
  • Jazz Pharmaceuticals Inc.$375
  • plus $3K from 35 others

What the payments were for

  • Speaking & faculty fees$38,77579%
  • Travel & lodging$2,3385%
  • Food & beverage$4,91410%
  • Education$2,9726%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,999 in reported general payments places this provider in the 85th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$96,091
Medicare patients
363
Services billed
739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate27$346,030
Trelegy ElliptaFluticasone/Umeclidin/Vilanter392$284,921
Breztri AerosphereBudesonide/Glycopyr/Formoterol102$67,837
Pirfenidone25$23,145
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr36$18,728
Stiolto RespimatTiotropium Br/Olodaterol Hcl34$17,730
Advair HfaFluticasone Propion/Salmeterol30$16,678
Breo ElliptaFluticasone/Vilanterol24$13,307
Spiriva RespimatTiotropium Bromide17$10,907
SymbicortBudesonide/Formoterol Fumarate24$8,330
Albuterol Sulfate HfaAlbuterol Sulfate237$4,804
Roflumilast49$4,402
Theophylline ErTheophylline Anhydrous23$3,483
Ventolin HfaAlbuterol Sulfate28$2,250
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine47$2,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$471$374,66778 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$437$316,955452 claims
AstraZenecaBreztri Aerosphere, Symbicort$40,548$76,167126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Chillicothe

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →